News & Resources

INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

April 4, 2022 Press Releases

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

February 8, 2022 Press Releases

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

December 21, 2021 Press Releases

Forsyth dentech 2021 “A Revolutionary Toothpaste Based Approach to Food Allergy Immunotherapy.”

September 24, 2021 Events

Intrommune Participates in the Forsyth dentech 2021 Conference

September 22, 2021 Press Releases

Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board

September 21, 2021 Press Releases

Unicorn Hunters

Corporate Deck

White Paper

Request your copy of our white paper

Videos

Want to learn more about Intrommune and our OMIT technology? Watch the videos below.

The time is now for a desensitization method that is safe, effective and easy to use. This is exactly the solution that Intrommune Therapeutics offers.

Tonya Winders

President, CEO
Allergy & Asthma Network